Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 28, 2016

View Archived Issues

European Commission awards orphan drug designation to SENS-401

Primary analysis results for phase III trial of tau-aggregation inhibitor therapy

Aptinyx presents in vitro and in vivo data for its NMDA receptor modulator JY-515317

Atom Bioscience and Pharmaceutical patents anticancer agents

Tarveda initiates phase I/IIa study of PEN-221 in SSTR2-expressing advanced cancers

FDA clears TopiVert's IND for phase I/IIa study of TOP-1630 in dry eye syndrome

GSK announces MAA submission to the EMA for Shingrix

Zebrafish model of fatty liver reveals role of 12-lipoxygenase

Chugai and Berlin-Chemie Menarini sign global license agreement for PA-799

Intellipharmaceutics submits NDA in U.S. for Rexista

Johnson & Johnson in preliminary discussions with Actelion

Ambroxol could be repurposed to treat fibromyalgia

AbbVie initiates phase I trial of ABBV-428 in advanced solid tumors

Phase III rheumatoid arthritis study finds equivalence between rituximab and biosimilar CT-P10

New TRPC4/5 inhibitor shows promise for anxiety and depression

HVTN initiates phase IIb/III trial of investigational HIV vaccine regimen in South Africa

Santen announces topline results from SAKURA phase III program of Opsiria

Data validate SIME Dx's lung maturity test for identifying infants at risk of RDS

Araim Pharmaceuticals' ARA-290 granted orphan drug designation in E.U.

Enrollment completed in phase IIa study of Serodus' SER-150

PharmaMar begins phase I study of lurbinectedin in Japan

Results mixed with everolimus and low-dose CIs in pediatric liver transplant recipients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...